Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, RANDOMISED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN, COMPARED WITH DAPAGLIFLOZIN, ON THE RISK OF HEART FAILURE EVENTS AND CARDIOVASCULAR DEATH IN PATIENTS WITH HEART FAILURE AND IMPAIRED KIDNEY FUNCTION

Intervention/treatment:
BALCINRENONE-DAPAGLIFLOZIN / DAPAGLIFLOZIN
Medical condition:
CHRONIC HEART FAILURE
Protocol code:
D6402C00012
Control number:
283363
Status:
Recruiting
Approved:
February 28, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06307652
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

British Columbia

Research Site
New Westminster, British Columbia, V3L 3W4
WITHDRAWN
Research Site
North Vancouver, British Columbia, V7M 2H4
WITHDRAWN
Research Site
Vancouver, British Columbia, V6Z 1Y6
WITHDRAWN

Manitoba

Research Site
Winnipeg, Manitoba, R2H 2A6
RECRUITING

Nova Scotia

Research Site
Sydney, Nova Scotia, B1P 1P3
RECRUITING

Ontario

Research Site
Cambridge, Ontario, N1R 6V6
COMPLETED
Research Site
Cambridge, Ontario, N1R 7R1
RECRUITING
Research Site
Hamilton, Ontario, L8L 5G4
RECRUITING
Research Site
London, Ontario, N6A 5A5
RECRUITING
Research Site
Newmarket, Ontario, L3Y 2P6
RECRUITING
Research Site
North York, Ontario, M6B 3H7
RECRUITING
Research Site
Oakville, Ontario, L6K 3W7
WITHDRAWN
Research Site
Oshawa, Ontario, L1J 2K1
TERMINATED
Research Site
Ottawa, Ontario, K1Y 4W7
WITHDRAWN
Research Site
Peterborough, Ontario, K9J 0B2
WITHDRAWN
Research Site
Thunder Bay, Ontario, P7B 7C7
RECRUITING
Research Site
Toronto, Ontario, M6G 1M2
RECRUITING
Research Site
Waterloo, Ontario, N2T 0C1
RECRUITING

Quebec

Research Site
Chicoutimi, Quebec, G7H 7K9
WITHDRAWN
Research Site
Greenfield Park, Quebec, J4V 2H1
RECRUITING
Research Site
Montreal, Quebec, H1T 1C8
RECRUITING
Research Site
Montreal, Quebec, H2X 0C1
RECRUITING
Research Site
Montreal, Quebec, H3G 1A4
WITHDRAWN
Research Site
Montreal, Quebec, H4J 1C5
RECRUITING
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4
RECRUITING
Research Site
Saint-Jean-sur-Richelieu, Quebec, J3A 1J2
WITHDRAWN
Research Site
Trois-Rivières, Quebec, G9A 4P3
RECRUITING
Did you find what you were looking for?